LLY SEC Filings
SEC filings for LLY. Annual and quarterly reports, 8-K events, Form 4 insider filings and 13D/G stake disclosures.
| Form | Filed | Accession |
|---|---|---|
| 10-Q | Aug 5, 2026 | 0000059478-26-000081EDGAR |
| 10-QAIEli Lilly reports exceptional Q1 2026 results (revenue +56%, net income +168%) and strong pipeline progress, including the FDA approval of Foundayo. | Apr 30, 2026 | 0000059478-26-000045EDGAR |
| 10-QAIEli Lilly reports exceptional results, with revenue up 54% and net income up sharply on Mounjaro and Zepbound, alongside pipeline successes and ample liquidity. | Oct 30, 2025 | 0000059478-25-000254EDGAR |
SEC filings for companies related to LLY
Never miss a LLY filing.
Get an email when LLY files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.